Suppr超能文献

[检查点激酶1和波罗样激酶1在胃良恶性病变中的表达及其临床病理意义]

[Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach].

作者信息

Yao Hongliang, Yang Zhulin, Li Yongguo

机构信息

Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Oct;35(10):1080-4. doi: 10.3969/j.issn.1672-7347.2010.10.008.

Abstract

OBJECTIVE

To determine the expressive level of checkpoint kinase 1 (CHK1) and polo-like kinase 1 (PLK1) and to detect their clinicopathological significance in benign and malignant lesions of the stomach.

METHODS

Envision Tm immunohistochemistry was used to detect the expression level of CHK1 and PLK1 in conventional paraffin-embedded sections from specimens of primary foci (n=59)and metastatic foci of lymph node (n=42) of gastric cancer, peritumoral tissues (n=20), and benign lesions of the stomach (n=95).

RESULTS

The positive rates of CHK1 were significantly higher in gastric cancer than that in different types of benign lesions(P<0.01). The positive rates of PLK1 were significantly higher in gastric cancer than that in peritumoral tissues (P<0.05) and different types of benign lesions (P<0.01), and the positive cases of PLK1 in benign lesion showed atypical hyperplasia. No significant difference of CHK1 and PLK1 expression was found between metastatic foci and corresponding primary foci (P>0.05). The positive rates of CHK1 and PLK1 were significantly lower in the non-metastatic lymph node than that in the metastatic lymph node (P<0.05). The positive rate of CHK1 was significantly lower in histologic grade II than that in the histologic grade III+IV (P<0.05). Positive correlation was found between the expression of CHK1 and PLK1 in gastric cancer tissues (P<0.01).

CONCLUSION

The expression level of CHK1 and /or PLK1 might be important biological markers of kinases to reflect the carcinogenesis, progression, biological behaviors, and guide clinical auxiliary treatment of gastric cancer.

摘要

目的

检测检查点激酶1(CHK1)和波罗蛋白样激酶1(PLK1)的表达水平,探讨其在胃良恶性病变中的临床病理意义。

方法

采用Envision Tm免疫组化法检测59例胃癌原发灶、42例胃癌转移淋巴结、20例癌旁组织及95例胃良性病变组织常规石蜡切片中CHK1和PLK1的表达水平。

结果

CHK1在胃癌中的阳性率显著高于不同类型的胃良性病变(P<0.01)。PLK1在胃癌中的阳性率显著高于癌旁组织(P<0.05)和不同类型的胃良性病变(P<0.01),胃良性病变中PLK1阳性病例表现为非典型增生。CHK1和PLK1在转移灶与相应原发灶中的表达差异无统计学意义(P>0.05)。CHK1和PLK1在无转移淋巴结中的阳性率显著低于有转移淋巴结(P<0.05)。CHK1在组织学Ⅱ级中的阳性率显著低于组织学Ⅲ+Ⅳ级(P<0.05)。胃癌组织中CHK1与PLK1的表达呈正相关(P<0.01)。

结论

CHK1和/或PLK1的表达水平可能是反映胃癌发生、发展、生物学行为及指导临床辅助治疗的重要激酶生物学标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验